Abstract For places where non-sterile drug production occurs. regulatory bodies recommend monitoring of the environmental bioburden. This procedure provides information regarding possible microbiological risks to which the products may be exposed. so that subsequent action measures may be implemented. https://www.jmannino.com/special-deal-A-Magazine-Curated-By-Sacai-quick-pick/